Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Advertisement
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 21, 2024
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
Read More
Katie KoskoASCO 2024: Focus on Lung Cancer | June 20, 2024
Certain patients appeared to derive the greatest benefit from the therapy.
Cecilia BrownNon-Small Cell Lung Cancer | June 18, 2024
The Biologics License Application is based upon data from the phase 3 PALOMA-3 study.
Nicolas Girard, MD, PhDASCO 2024: Focus on Lung Cancer | June 12, 2024
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
Cecilia BrownLung Cancer | June 11, 2024
The supplemental New Drug Application is based on data from the phase 3 LAURA trial.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 10, 2024
The study findings "add critical evidence to support ongoing access to telehealth services" in these patients.
Cecilia BrownAdvancements in Oncology | June 14, 2024
Dr. Manochakian discusses new data and why next-generation sequencing is a critical step when treating NSCLC.
Cecilia BrownAdvancements in Oncology | June 14, 2024
The Oncology Brothers and Dr. Manochakian discussed the rapid changes in the perioperative treatment landscape for NSCLC.
Suresh S. Ramalingam, MD, FACP, FASCOASCO 2024: Focus on Lung Cancer | June 5, 2024
Samantha Armstrong, MD, and Karine Tawagi, MD, interview Dr. Ramalingam about his plenary presentation.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 4, 2024
An unexpected result suggests the route of administration or formulation of amivantamab may affect outcomes.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 3, 2024
First-line nivolumab plus ipilimumab and chemotherapy maintained a "long-term, durable survival benefit."
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 5, 2024
The results may establish osimertinib as the new standard of care for EGFR-mutated NSCLC in a certain setting.
Cecilia BrownASCO 2024: Focus on Lung Cancer | June 2, 2024
Ultrasensitive MRD detection may "promising for use in risk-adapted trials in early-stage NSCLC.”
Cecilia BrownASCO 2024: Focus on Lung Cancer | May 31, 2024
The combination showed significantly improved median PFS compared with osimertinib in patients with certain features.
Cecilia BrownASCO 2024: Focus on Lung Cancer | May 31, 2024
The primary end point of the phase 3 HARMONi-A trial was PFS in the intention-to-treat population.
Cecilia BrownASCO 2024: Focus on Lung Cancer | May 31, 2024
The median PFS of patients receiving lorlatinib in the phase 3 CROWN study has yet to be reached with 5 years of follow-up.
Cecilia BrownNon-Small Cell Lung Cancer | May 29, 2024
Exosomal circRNAs are “potential novel biomarkers for several cancers."
Cecilia BrownNon-Small Cell Lung Cancer | May 20, 2024
The trial evaluated nivolumab plus CCRT followed by nivolumab plus ipilimumab versus CCRT followed by durvalumab.
Mary GreccoNon-Small Cell Lung Cancer | April 30, 2024
Cancer organoid-based drug sensitivity tests have recently been investigated to predict responses to anticancer drugs.
Mary GreccoLung Cancer | April 30, 2024
A study that assessed the impact of miR-29a and miR-143 on gene expression in lung cancer.
Advertisement
Advertisement
Advertisement
Latest News

June 21, 2024